{"created":"2025-01-29T05:39:45.337559+00:00","id":2000312,"links":{},"metadata":{"_buckets":{"deposit":"27600747-2b74-4d7c-96c5-2831df38f601"},"_deposit":{"created_by":3,"id":"2000312","owner":"3","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"2000312"},"status":"published"},"_oai":{"id":"oai:asahikawa-med.repo.nii.ac.jp:02000312","sets":["7:27:45"]},"author_link":[],"item_10_alternative_title_3":{"attribute_name":"その他(別言語等)のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"リン酸化ビメンチンを標的とした大腸癌に対する腫瘍反応性ヘルパーT細胞応答に関する研究","subitem_alternative_title_language":"ja"}]},"item_10_biblio_info_21":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020-06-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"999","bibliographicPageStart":"989","bibliographicVolumeNumber":"69","bibliographic_titles":[{"bibliographic_title":"Cancer immunology and immunotherapy CII","bibliographic_titleLang":"en"}]}]},"item_10_date_granted_30":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2022-12-23"}]},"item_10_degree_grantor_32":{"attribute_name":"item_10_degree_grantor_32","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"旭川医科大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"10107","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10_degree_name_31":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士(医学)","subitem_degreename_language":"ja"}]},"item_10_description_28":{"attribute_name":"識別番号 その他","attribute_value_mlt":[{"subitem_description":"PMID:32086539","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10_description_33":{"attribute_name":"item_10_description_33","attribute_value_mlt":[{"subitem_description":"Colorectal cancer (CRC) patients with metastatic lesions have low 5-year survival rates. During metastasis, cancer cells often obtain unique characteristics such as epithelial-mesenchymal transition (EMT). Vimentin a biomarker contributes to EMT by changing cell shape and motility. Since abnormal phosphorylation is a hallmark of malignancy, targeting phosphorylated vimentin is a feasible approach for the treatment of metastatic tumors while sparing non-tumor cells. Recent evidence has revealed that both CD8 cytotoxic T lymphocytes (CTLs) and also CD4 helper T lymphocytes (HTLs) can distinguish post-translationally modified antigens from normal antigens. Here, we showed that the expression of phosphorylated vimentin was upregulated in metastatic sites of CRC. We also showed that a chemotherapeutic reagent augmented the expression of phosphorylated vimentin. The novel phosphorylated helper peptide epitopes from vimentin could elicit a sufficient T cell response. Notably, precursor lymphocytes that specifically reacted to these phosphorylated vimentin-derived peptides were detected in CRC patients. These results suggest that immunotherapy targeting phosphorylated vimentin could be promising for metastatic CRC patients.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10_dissertation_number_29":{"attribute_name":"dissertation_number","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第585号"}]},"item_10_relation_24":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s00262-020-02524-9","subitem_relation_type_select":"DOI"}}]},"item_10_source_id_22":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0340-7004","subitem_source_identifier_type":"PISSN"}]},"item_10_version_type_38":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"大原, みずほ","creatorNameLang":"ja","creatorNameType":"Personal"},{"creatorName":"オオハラ, ミズホ","creatorNameLang":"ja-Kana","creatorNameType":"Personal"},{"creatorName":"Ohara, Mizuho","creatorNameLang":"en","creatorNameType":"Personal"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-01-04"}],"filename":"K585 Ohara Mizuho_TD.pdf","filesize":[{"value":"1.1 MB"}],"format":"application/pdf","url":{"objectType":"fulltext","url":"https://asahikawa-med.repo.nii.ac.jp/record/2000312/files/K585 Ohara Mizuho_TD.pdf"},"version_id":"fa500082-a934-499e-bd00-e3ee3f5c807a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"CD4 T cell","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Colorectal cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Epitope","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Phosphorylation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Post-translational modification","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Vimentin","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer","subitem_title_language":"en"}]},"item_type_id":"10","owner":"3","path":["45"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-01-04"},"publish_date":"2023-01-04","publish_status":"0","recid":"2000312","relation_version_is_last":true,"title":["Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2025-01-29T05:46:18.491425+00:00"}